

Anetta Undas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2714501/publications.pdf>

Version: 2024-02-01

214
papers

4,455
citations

182225

30
h-index

169272

56
g-index

215
all docs

215
docs citations

215
times ranked

4836
citing authors

#	ARTICLE	IF	CITATIONS
1	Isoprostane and GDF15 as novel markers of post-PE syndrome: Relation with prothrombotic factors. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13660.	1.7	3
2	Caprini VTE computerized risk assessment improves the use of thromboprophylaxis in hospitalized patients with pulmonary disorders. <i>Advances in Clinical and Experimental Medicine</i> , 2022, 31, 261-266.	0.6	0
3	Apolipoproteins and lipoprotein(a) as factors modulating fibrin clot properties in patients with severe aortic stenosis. <i>Atherosclerosis</i> , 2022, 344, 49-56.	0.4	5
4	8-Isoprostanes and Asymmetric Dimethylarginine as Predictors of Mortality in Patients Following Coronary Bypass Surgery: A Long-Term Follow-Up Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 246.	1.0	3
5	Active factor XI is associated with the risk of cardiovascular events in stable coronary artery disease patients. <i>Atherosclerosis</i> , 2022, 346, 124-132.	0.4	10
6	Active FXI Can Independently Predict Ischemic Stroke in Anticoagulated Atrial Fibrillation Patients: A Cohort Study. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1397-1406.	1.8	4
7	Knowledge about atrial fibrillation and anticoagulation affects the risk of clinical outcomes. <i>Thrombosis Research</i> , 2022, 213, 105-112.	0.8	5
8	Markers of NET formation and stroke risk in patients with atrial fibrillation: association with a prothrombotic state. <i>Thrombosis Research</i> , 2022, 213, 1-7.	0.8	13
9	Intensive low-density lipoprotein cholesterol lowering improves fibrin clot properties: Association with lipoproteins and C-reactive protein. <i>Vascular Pharmacology</i> , 2022, 144, 106977.	1.0	8
10	Direct oral anticoagulants in patients with severe inherited thrombophilia: a single-center cohort study. <i>International Journal of Hematology</i> , 2021, 113, 190-198.	0.7	7
11	Direct oral anticoagulants in the prevention of stroke in breast cancer patients with atrial fibrillation during adjuvant endocrine therapy: A cohort study. <i>International Journal of Cardiology</i> , 2021, 324, 78-83.	0.8	10
12	Afibrinogenemia caused by a novel homozygous missense mutation, FGB p.Cys241Tyr, in a male patient with recurrent intracranial bleeding: case report and review of literature. <i>Haemophilia</i> , 2021, 27, 26-32.	1.0	2
13	Determinants of plasma fibrin clot lysis measured using three different assays in healthy subjects. <i>Thrombosis Research</i> , 2021, 197, 1-7.	0.8	18
14	Cellular fibronectin promotes deep vein thrombosis in diet-induced obese mice. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 814-821.	1.9	5
15	Von Willebrand factor in aortic or mitral valve stenosis and bleeding after heart valve surgery. <i>Thrombosis Research</i> , 2021, 198, 190-195.	0.8	1
16	Glycation and acetylation sites on fibrinogen in plasma fibrin clot of patients with type 2 diabetes: Effects of low-dose acetylsalicylic acid. <i>Thrombosis Research</i> , 2021, 198, 93-98.	0.8	3
17	Professor Franciszek Kokot and his successor, Professor Andrzej Januszewicz: the Polish Co-Chair of the Scientific Board of <i>Polish Archives of Internal Medicine</i> . <i>Polish Archives of Internal Medicine</i> , 2021, 131, 114-115.	0.3	0
18	Aortic valvular stenosis: Novel therapeutic strategies. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13527.	1.7	4

#	ARTICLE	IF	CITATIONS
19	Fibrinolysis in Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 480-489.	1.5	7
20	Via Medica comes back as the publisher of <i>Kardiologia Polska</i> . <i>Kardiologia Polska</i> , 2021, 79, 371-372.	0.3	0
21	A new editor in <i>Polish Archives of Internal Medicine</i> : welcome to Professor Tomasz StompÅr. <i>Polish Archives of Internal Medicine</i> , 2021, 131, 320-321.	0.3	0
22	Unsolved issues of The Efficacy and Safety of Edoxaban. , 2021, 25, 460-460.		1
23	Right ventricular echocardiographic parameters associated with prothrombotic abnormalities in normotensive patients with acute pulmonary embolism. <i>International Journal of Cardiology</i> , 2021, 333, 195-201.	0.8	1
24	Reduced-dose apixaban and dabigatran in patients with advanced liver cirrhosis and venous thromboembolism: a case series. <i>Polish Archives of Internal Medicine</i> , 2021, 131, 762-765.	0.3	2
25	Fibrin Clot Properties in Atherosclerotic Vascular Disease: From Pathophysiology to Clinical Outcomes. <i>Journal of Clinical Medicine</i> , 2021, 10, 2999.	1.0	27
26	NOAC in patients with VTE and polycythemia vera or essential thrombocythemia. <i>Journal of Cardiovascular Pharmacology</i> , 2021, Publish Ahead of Print, e743-e748.	0.8	2
27	The highest Impact Factor of <i>Kardiologia Polska</i> announced in June 2021: we did it!. <i>Kardiologia Polska</i> , 2021, 79, 723-724.	0.3	0
28	Hypofibrinolysis in type 2 diabetes and its clinical implications: from mechanisms to pharmacological modulation. <i>Cardiovascular Diabetology</i> , 2021, 20, 191.	2.7	20
29	Diabetes concomitant to aortic stenosis is associated with increased expression of NF-ÎB and more pronounced valve calcification. <i>Diabetologia</i> , 2021, 64, 2562-2574.	2.9	13
30	Current treatment challenges in the COVID-19 pandemic. <i>Polish Archives of Internal Medicine</i> , 2021, 131, 854-861.	0.3	20
31	Family History of Stroke is Associated with Greater Prevalence of Certain Risk Factors and Self-Reported Stroke Symptoms. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 106074.	0.7	1
32	Loose Fibrin Clot Structure and Increased Susceptibility to Lysis Characterize Patients with Central Acute Pulmonary Embolism: The Impact of Isolated Embolism. <i>Thrombosis and Haemostasis</i> , 2021, 121, 529-537.	1.8	7
33	Accelerated fibrin clot degradation is associated with arterial thromboembolism in patients following venous thrombosis: a cohort study. <i>Scientific Reports</i> , 2021, 11, 21003.	1.6	1
34	Thromboembolism and bleeding in patients with atrial fibrillation and stage 4 chronic kidney disease: impact of biomarkers. <i>Kardiologia Polska</i> , 2021, 79, 1086-1092.	0.3	11
35	Towards Personalized Therapy of Aortic Stenosis. <i>Journal of Personalized Medicine</i> , 2021, 11, 1292.	1.1	2
36	<i>Kardiologia Polska</i> at the end of 2021: The pandemic and beyond. <i>Kardiologia Polska</i> , 2021, 79, 1299-1300.	0.3	0

#	ARTICLE	IF	CITATIONS
37	New publisher of <i>Kardiologia Polska</i> : what do we hope for in May 2021?. <i>Kardiologia Polska</i> , 2021, 79, 487.	0.3	0
38	Altered fibrin clot properties and fibrinolysis in patients with atrial fibrillation: practical implications. <i>Europace</i> , 2020, 22, 185-194.	0.7	8
39	Bleeding Tolerance Among Patients With Atrial Fibrillation on Oral Anticoagulation. <i>Canadian Journal of Cardiology</i> , 2020, 36, 500-508.	0.8	8
40	Clot Lysis Time Predicts Stroke During Anticoagulant Therapy in Patients with Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2020, 36, 119-126.	0.8	13
41	Association of NT-proBNP and GDF-15 with markers of a prothrombotic state in patients with atrial fibrillation off anticoagulation. <i>Clinical Research in Cardiology</i> , 2020, 109, 426-434.	1.5	16
42	Fibrin Clot Properties and Thrombin Generation in Hypertrophic Cardiomyopathy. <i>Thrombosis and Haemostasis</i> , 2020, 120, 181-183.	1.8	3
43	Sex-specific alteration to α_2 -antiplasmin incorporation in patients with type 2 diabetes. <i>Thrombosis Research</i> , 2020, 185, 55-62.	0.8	8
44	Identification of glycosylated and acetylated lysine residues in human α_2 -antiplasmin. <i>Biochemical and Biophysical Research Communications</i> , 2020, 521, 19-23.	1.0	3
45	Direct oral anticoagulants in patients with antiphospholipid syndrome: a cohort study. <i>Lupus</i> , 2020, 29, 37-44.	0.8	31
46	Coagulation factors and fibrinolytic activity in the left atrial appendage and other heart chambers in patients with atrial fibrillation: is there a local intracardiac prothrombotic state? (HEART-CLOT) <i>Thrombosis and Haemostasis</i> , 2020, 120, 181-183.	0.8	108
47	Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. <i>The Cochrane Library</i> , 2020, 10, CD012169.	1.5	18
48	Effect of enoxaparin on plasma fibrin clot properties and fibrin structure in patients with acute pulmonary embolism. <i>Vascular Pharmacology</i> , 2020, 133-134, 106783.	1.0	7
49	Plasma fibrin clot proteomics in patients with acute pulmonary embolism: Association with clot properties. <i>Journal of Proteomics</i> , 2020, 229, 103946.	1.2	14
50	Interaction between functional polymorphisms in FCER1A and TLR2 and the severity of atopic dermatitis. <i>Human Immunology</i> , 2020, 81, 709-713.	1.2	5
51	Citrullinated histone H3, a marker of extracellular trap formation, is increased in blood of stable asthma patients. <i>Clinical and Translational Allergy</i> , 2020, 10, 31.	1.4	20
52	Prothrombotic fibrin clot properties associated with NETs formation characterize acute pulmonary embolism patients with higher mortality risk. <i>Scientific Reports</i> , 2020, 10, 11433.	1.6	30
53	Chronic Kidney Disease and Its Impact on a Prothrombotic State in Patients with Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2020, 9, 2476.	1.0	9
54	Impaired Fibrinolysis in Patients with Isolated Aortic Stenosis is Associated with Enhanced Oxidative Stress. <i>Journal of Clinical Medicine</i> , 2020, 9, 2002.	1.0	15

#	ARTICLE	IF	CITATIONS
55	Acceptance of a potential major bleeding among patients with venous thromboembolism on long-term oral anticoagulation: the knowledge of the disease and therapy matters. <i>Thrombosis Research</i> , 2020, 193, 116-121.	0.8	3
56	Effects of rivaroxaban and dabigatran on local expression of coagulation and inflammatory factors within human aortic stenotic valves. <i>Vascular Pharmacology</i> , 2020, 130, 106679.	1.0	9
57	Accumulation of advanced glycation end products (AGEs) is associated with the severity of aortic stenosis in patients with concomitant type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2020, 19, 92.	2.7	40
58	Delayed Thrombin Generation Is Associated with Minor Bleedings in Venous Thromboembolism Patients on Rivaroxaban: Usefulness of Calibrated Automated Thrombography. <i>Journal of Clinical Medicine</i> , 2020, 9, 2018.	1.0	7
59	Plasma Fibrin Clot Properties as Determinants of Bleeding Time in Human Subjects: Association with Histidine-Rich Glycoprotein. <i>Disease Markers</i> , 2020, 2020, 1-11.	0.6	5
60	A prothrombotic state and denser clot formation in patients following acute limb ischemia of unknown cause. <i>Thrombosis Research</i> , 2020, 187, 32-38.	0.8	6
61	Elevated Lactate Levels in Acute Pulmonary Embolism Are Associated with Prothrombotic Fibrin Clot Properties: Contribution of NETs Formation. <i>Journal of Clinical Medicine</i> , 2020, 9, 953.	1.0	22
62	Bleeding in anticoagulated patients with atrial fibrillation: practical considerations. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 47-58.	0.3	11
63	Bleeding in anticoagulated patients with atrial fibrillation: practical considerations. <i>Kardiologia Polska</i> , 2020, 78, 105-116.	0.3	9
64	Guidance for anticoagulation management in venous thromboembolism during the coronavirus disease 2019 pandemic in Poland: an expert opinion of the Section on Pulmonary Circulation of the Polish Cardiac Society. <i>Kardiologia Polska</i> , 2020, 78, 642-646.	0.3	16
65	Polish Archives of Internal Medicine in the coronavirus disease 2019 pandemic. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 263-263.	0.3	0
66	A new impact factor of <i>Kardiologia Polska</i> . <i>Kardiologia Polska</i> , 2020, 78, 653-654.	0.3	0
67	Efficacy and safety of non-vitamin K antagonist oral anticoagulants in very elderly patients with atrial fibrillation: a single-center experience. <i>Kardiologia Polska</i> , 2020, 78, 154-157.	0.3	2
68	Cellular Fibronectin Promotes Deep Vein Thrombosis in Obese Mice. <i>Blood</i> , 2020, 136, 19-20.	0.6	0
69	Prothrombotic fibrin clot properties are associated with post-discharge venous thromboembolism in acutely ill medical patients. <i>Thrombosis Research</i> , 2019, 182, 141-149.	0.8	2
70	Prothrombotic clot properties can predict venous ulcers in patients following deep vein thrombosis: a cohort study. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 603-609.	1.0	8
71	Genetic and clinical characterization of congenital fibrinogen disorders in Polish patients: Identification of three novel fibrinogen gamma chain mutations. <i>Thrombosis Research</i> , 2019, 182, 133-140.	0.8	19
72	Plasma fibrin clot proteomics in healthy subjects: Relation to clot permeability and lysis time. <i>Journal of Proteomics</i> , 2019, 208, 103487.	1.2	24

#	ARTICLE	IF	CITATIONS
73	Fibrin biofilm can be detected on intracoronary thrombi aspirated from patients with acute myocardial infarction. <i>Cardiovascular Research</i> , 2019, 115, 1026-1028.	1.8	9
74	Polyhedral erythrocytes in intracoronary thrombus and their association with reperfusion in myocardial infarction. <i>Clinical Research in Cardiology</i> , 2019, 108, 950-962.	1.5	14
75	Prothrombotic State in Atrial Fibrillation Patients With One Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex). <i>Canadian Journal of Cardiology</i> , 2019, 35, 634-643.	0.8	13
76	A Prothrombotic State in Patients With a History of Left Ventricular Thrombus. <i>American Journal of Cardiology</i> , 2019, 123, 1358-1363.	0.7	6
77	Improving fibrinolysis in venous thromboembolism: impact of fibrin structure. <i>Expert Review of Hematology</i> , 2019, 12, 597-607.	1.0	12
78	Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study. <i>Vascular Pharmacology</i> , 2019, 120, 106567.	1.0	9
79	Increased activity of lipoprotein-associated phospholipase A2 in non-severe asthma. <i>Allergology International</i> , 2019, 68, 450-455.	1.4	8
80	High prevalence of inherited thrombophilia and antiphospholipid syndrome in myocardial infarction with non-obstructive coronary arteries: Comparison with cryptogenic stroke. <i>International Journal of Cardiology</i> , 2019, 290, 1-6.	0.8	35
81	Predictors of neutrophil extracellular traps markers in type 2 diabetes mellitus: associations with a prothrombotic state and hypofibrinolysis. <i>Cardiovascular Diabetology</i> , 2019, 18, 49.	2.7	47
82	NETosis is associated with the severity of aortic stenosis: Links with inflammation. <i>International Journal of Cardiology</i> , 2019, 286, 121-126.	0.8	20
83	Decreased Levels of Histidine-Rich Glycoprotein in Advanced Lung Cancer: Association with Prothrombotic Alterations. <i>Disease Markers</i> , 2019, 2019, 1-7.	0.6	17
84	Altered fibrin clot properties in advanced lung cancer: strong impact of cigarette smoking. <i>Medical Oncology</i> , 2019, 36, 37.	1.2	6
85	Restenosis is associated with prothrombotic plasma fibrin clot characteristics in endovascularly treated patients with critical limb ischemia. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 540-549.	1.0	5
86	Recurrent venous thromboembolism patients form clots with lower elastic modulus than those formed by patients with non-recurrent disease. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 618-626.	1.9	24
87	High detection rates of antithrombin deficiency and antiphospholipid syndrome in outpatients aged over 50 years using the standardized protocol for thrombophilia screening. <i>Thrombosis Research</i> , 2019, 176, 67-73.	0.8	8
88	Plasma Fibrin Clot Properties Are Unfavorably Altered in Women following Venous Thromboembolism Associated with Combined Hormonal Contraception. <i>Disease Markers</i> , 2019, 2019, 1-9.	0.6	4
89	MPI-CDG with transient hypoglycosylation and antithrombin deficiency. <i>Haematologica</i> , 2019, 104, e79-e82.	1.7	12
90	Plasma Protein Oxidation as a Determinant of Impaired Fibrinolysis in Type 2 Diabetes. <i>Thrombosis and Haemostasis</i> , 2019, 119, 213-222.	1.8	14

#	ARTICLE	IF	CITATIONS
91	Altered Fibrin Clot Properties Predict Stroke and Bleedings in Patients With Atrial Fibrillation on Rivaroxaban. <i>Stroke</i> , 2019, 50, 185-188.	1.0	8
92	Elevated lipoprotein(a) as a new risk factor of cerebral venous sinus thrombosis: association with fibrin clot properties. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 8-15.	1.0	14
93	Plasma clot permeability and lysis determined on rivaroxaban and clinical outcomes in patients with venous thromboembolism: a cohort study. <i>Polish Archives of Internal Medicine</i> , 2019, 129, 377-385.	0.3	11
94	Fibrinogen Å³dÅ³: a new cause of dysfibrinogenemia associated with recurrent thromboembolic arterial events. <i>Polish Archives of Internal Medicine</i> , 2019, 129, 934-935.	0.3	1
95	Determination and interpretation of MTHFR gene mutations in gynecology and internal medicine. <i>Polish Archives of Internal Medicine</i> , 2019, 129, 728-732.	0.3	5
96	Congenital structural and functional fibrinogen disorders: a primer for internists. <i>Polish Archives of Internal Medicine</i> , 2019, 129, 913-920.	0.3	10
97	The ORBIT bleeding score is associated with lysis and permeability of fibrin clots. <i>Kardiologia Polska</i> , 2019, 77, 1182-1185.	0.3	3
98	Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and colorectal cancer: a single-center experience. <i>Kardiologia Polska</i> , 2019, 77, 1186-1189.	0.3	4
99	How to improve the management of a patient with HIT? Comments on a case report by GÅner A. et al.. <i>Anatolian Journal of Cardiology</i> , 2019, 22, 339.	0.5	0
100	Atrial fibrillation and rapid atrial pacing are linked to enhanced inflammation and altered fibrinolysis in patients undergoing pulmonary vein isolation. <i>Kardiologia Polska</i> , 2019, 77, 386-388.	0.3	3
101	Welcome to <i>Medycyna Praktyczna</i> : the Editor's comments. <i>Kardiologia Polska</i> , 2019, 77, 413-414.	0.3	0
102	Continuous growth of the journal. <i>Polish Archives of Internal Medicine</i> , 2019, 129, 362-364.	0.3	0
103	Vascular Ehlers-Danlos syndrome in 2 Polish patients: identification of 2 novel COL3A1 gene mutations. <i>Kardiologia Polska</i> , 2019, 77, 1070-1073.	0.3	2
104	<i>Kardiologia Polska</i> in 2019 and a look into the future. <i>Kardiologia Polska</i> , 2019, 77, 1117-1118.	0.3	0
105	Elevated thrombin generation and factor VIII activity during angioedema attack in patients with hereditary C1 inhibitor deficiency. <i>Polish Archives of Internal Medicine</i> , 2019, 129, 936-938.	0.3	0
106	Reduced plasma fibrin clot permeability is associated with recurrent thromboembolic events in patients with antiphospholipid syndrome. <i>Rheumatology</i> , 2018, 57, 1340-1349.	0.9	11
107	Altered Plasma Clot Properties and Trauma-Related Venous Thromboembolism despite Thromboprophylaxis. <i>Thrombosis and Haemostasis</i> , 2018, 47, 654-663.	1.8	4
108	Antiplatelet and Anticoagulant Agents for Secondary Prevention of Thromboembolic Events in People With Antiphospholipid Syndrome. <i>Stroke</i> , 2018, 49, .	1.0	1

#	ARTICLE	IF	CITATIONS
109	Impaired plasminogen binding in patients with venous thromboembolism: Association with protein carbonylation. <i>Thrombosis Research</i> , 2018, 163, 12-18.	0.8	3
110	Erythrocyte compression index is impaired in patients with residual vein obstruction. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 31-38.	1.0	7
111	Altered plasma clot properties increase the risk of recurrent deep vein thrombosis: a cohort study. <i>Blood</i> , 2018, 131, 797-807.	0.6	63
112	Altered fibrin clot properties in advanced lung cancer: impact of chemotherapy. <i>Journal of Thoracic Disease</i> , 2018, 10, 6863-6872.	0.6	6
113	In silico thrombin and factor Xa generation profiles in adult patients after Fontan operation. <i>Blood Coagulation and Fibrinolysis</i> , 2018, 29, 236-240.	0.5	4
114	Differences in plasma fibrin clot composition in patients with thrombotic antiphospholipid syndrome compared with venous thromboembolism. <i>Scientific Reports</i> , 2018, 8, 17301.	1.6	25
115	Polyhedrocytes in blood clots of type 2 diabetic patients with high cardiovascular risk: association with glycemia, oxidative stress and platelet activation. <i>Cardiovascular Diabetology</i> , 2018, 17, 146.	2.7	12
116	Impaired fibrinolysis in degenerative mitral and aortic valve stenosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 193-202.	1.0	3
117	Increased blood levels of cellular fibronectin in asthma: Relation to the asthma severity, inflammation, and prothrombotic blood alterations. <i>Respiratory Medicine</i> , 2018, 141, 64-71.	1.3	23
118	Altered structure and function of fibrinogen after cleavage by Factor VII Activating Protease (FSAP). <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 3397-3406.	1.8	11
119	Relationship between polyunsaturated fatty acid composition in serum phospholipids, systemic low-grade inflammation, and glycemic control in patients with type 2 diabetes and atherosclerotic cardiovascular disease. <i>Cardiovascular Diabetology</i> , 2018, 17, 29.	2.7	33
120	Real-life use of thromboprophylaxis in patients hospitalized for pulmonary disorders: A single-center retrospective study. <i>Advances in Clinical and Experimental Medicine</i> , 2018, 27, 237-243.	0.6	3
121	Non-classical and intermediate monocytes in patients following venous thromboembolism: Links with inflammation. <i>Advances in Clinical and Experimental Medicine</i> , 2018, 28, 51-58.	0.6	13
122	Knowledge gaps in patients with venous thromboembolism: usefulness of a new questionnaire. <i>Polish Archives of Internal Medicine</i> , 2018, 129, 28-35.	0.3	6
123	Association of cardiac troponin I with prothrombotic alterations in atrial fibrillation. <i>Kardiologia Polska</i> , 2018, 76, 1106-1109.	0.3	12
124	Angiotensin-converting enzyme inhibitors modulate the activation of the tissue factor pathway within aortic valves in patients with aortic stenosis: Links between blood coagulation and inflammation. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2018, 72, 1208-1215.	0.1	1
125	Statins in prevention of venous thromboembolism. <i>Lancet Haematology</i> , 2017, 4, e61-e62.	2.2	2
126	Prothrombotic Fibrin Clot Phenotype Is Associated With Recurrent Pulmonary Embolism After Discontinuation of Anticoagulant Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 365-373.	1.1	45

#	ARTICLE	IF	CITATIONS
127	Prothrombotic State in Asthma Is Related to Increased Levels of Inflammatory Cytokines, IL-6 and TNF α , in Peripheral Blood. <i>Inflammation</i> , 2017, 40, 1225-1235.	1.7	32
128	Elevated NT-proBNP is associated with unfavorably altered plasma fibrin clot properties in atrial fibrillation. <i>International Journal of Cardiology</i> , 2017, 243, 244-250.	0.8	16
129	Non-vitamin K antagonist oral anticoagulants in patients with severe inherited thrombophilia. <i>Blood Coagulation and Fibrinolysis</i> , 2017, 28, 438-442.	0.5	26
130	The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome. <i>Thrombosis Research</i> , 2017, 152, 93-97.	0.8	49
131	Effects of ultra-low-dose versus standard hormone therapy on fibrinolysis and thrombin generation in postmenopausal women. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 217, 77-82.	0.5	3
132	Fibrin Clot Permeability as a Predictor of Stroke and Bleeding in Anticoagulated Patients With Atrial Fibrillation. <i>Stroke</i> , 2017, 48, 2716-2722.	1.0	37
133	Impaired fibrinolysis and lower levels of plasma α 2-macroglobulin are associated with an increased risk of severe asthma exacerbations. <i>Scientific Reports</i> , 2017, 7, 11014.	1.6	11
134	Effects of tibolone on fibrinogen and antithrombin III: A systematic review and meta-analysis of controlled trials. <i>Pharmacological Research</i> , 2017, 124, 64-73.	3.1	4
135	Determination of Fibrinogen and Thrombin Time (TT). <i>Methods in Molecular Biology</i> , 2017, 1646, 105-110.	0.4	33
136	Plasma fibrin clot properties in the G20210A prothrombin mutation carriers following venous thromboembolism: the effect of rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1739-1749.	1.8	20
137	Specific changes in circulating cytokines and growth factors induced by exercise stress testing in asymptomatic aortic valve stenosis. <i>PLoS ONE</i> , 2017, 12, e0173787.	1.1	8
138	Optimization of quantitative proteomic analysis of clots generated from plasma of patients with venous thromboembolism. <i>Clinical Proteomics</i> , 2017, 14, 38.	1.1	24
139	Fibrin clot characteristics in acute ischaemic stroke patients treated with thrombolysis: the impact on clinical outcome. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1440-1447.	1.8	27
140	Acute-phase proteins and oxidative stress in patients undergoing coronary artery bypass graft: comparison of cardioplegia strategy. <i>Kardiochirurgia I Torakochirurgia Polska</i> , 2017, 1, 16-21.	0.1	2
141	Interplay between elevated cellular fibronectin and plasma fibrin clot properties in type 2 diabetes. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1671-1678.	1.8	9
142	Genetic characterization of antithrombin, protein C and protein S deficiencies in Polish patients. <i>Polish Archives of Internal Medicine</i> , 2017, 127, 512-523.	0.3	23
143	Plasma fibrin clot structure and thromboembolism: clinical implications. <i>Polish Archives of Internal Medicine</i> , 2017, 127, 873-881.	0.3	59
144	Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases. <i>World Journal of Gastroenterology</i> , 2017, 23, 4796.	1.4	10

#	ARTICLE	IF	CITATIONS
145	Prediction of unstable anticoagulation with acenocoumarol versus warfarin in atrial fibrillation. <i>Cardiology Journal</i> , 2017, 24, 477-483.	0.5	5
146	Neutrophil extracellular traps formation in patients with eosinophilic granulomatosis with polyangiitis: association with eosinophilic inflammation. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 27-32.	0.4	8
147	Determinants of hypofibrinolysis in patients with digestive tract cancer. <i>Przegląd Gastroenterologiczny</i> , 2016, 2, 104-110.	0.3	5
148	Activated factor IX, factor XI and tissue factor identify patients with permanent atrial fibrillation treated with warfarin who are at risk of ischemic stroke. <i>Archives of Medical Science</i> , 2016, 5, 1000-1007.	0.4	12
149	Preoperative values of inflammatory markers predict clinical outcomes in patients after CABG, regardless of the use of cardiopulmonary bypass. <i>Indian Heart Journal</i> , 2016, 68, S10-S15.	0.2	21
150	How to Assess Fibrinogen Levels and Fibrin Clot Properties in Clinical Practice?. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 381-388.	1.5	49
151	Meta-analysis of uninterrupted as compared to interrupted oral anticoagulation with or without bridging in patients undergoing coronary angiography with or without percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2016, 223, 186-194.	0.8	29
152	Heavy menstrual bleeding in women treated with rivaroxaban and vitamin K antagonists and the risk of recurrent venous thromboembolism. <i>Vascular Pharmacology</i> , 2016, 87, 242-247.	1.0	45
153	Prothrombotic State in Patients With a Left Atrial Appendage Thrombus of Unknown Origin and Cerebrovascular Events. <i>Stroke</i> , 2016, 47, 1872-1878.	1.0	20
154	Fibrin structure in organized thrombotic material removed during pulmonary artery endarterectomy: the effect of vessel calibre. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 212-217.	1.0	8
155	On antithrombotic mechanisms of statins: Are they relevant in intracerebral or subarachnoid bleedings?. <i>Neurologia i Neurochirurgia Polska</i> , 2016, 50, 141-142.	0.6	0
156	Direct Oral Anticoagulants in Patients with Thrombophilia: Challenges in Diagnostic Evaluation and Treatment. <i>Advances in Clinical and Experimental Medicine</i> , 2016, 25, 1321-1330.	0.6	15
157	Practical considerations on non-vitamin K oral anticoagulants in patients with high body weight. <i>Anatolian Journal of Cardiology</i> , 2016, 16, 220.	0.5	0
158	Commentary to the article: "Rivaroxaban in secondary cardiogenic stroke prevention: two-year single-centre experience based on follow-up of 209 patients". <i>Kardiologia Polska</i> , 2016, 74, 504-505.	0.3	0
159	Induction therapy alters plasma fibrin clot properties in multiple myeloma patients. <i>Blood Coagulation and Fibrinolysis</i> , 2015, 26, 621-627.	0.5	19
160	Association of the C-Reactive Protein Gene (CRP) rs1205 C>T Polymorphism with Aortic Valve Calcification in Patients with Aortic Stenosis. <i>International Journal of Molecular Sciences</i> , 2015, 16, 23745-23759.	1.8	12
161	Increased Plasma Clot Permeability and Susceptibility to Lysis Are Associated with Heavy Menstrual Bleeding of Unknown Cause: A Case-Control Study. <i>PLoS ONE</i> , 2015, 10, e0125069.	1.1	17
162	Increased Oxidation as an Additional Mechanism Underlying Reduced Clot Permeability and Impaired Fibrinolysis in Type 2 Diabetes. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-8.	1.0	21

#	ARTICLE	IF	CITATIONS
163	Denser plasma clot formation and impaired fibrinolysis in paroxysmal and persistent atrial fibrillation while on sinus rhythm: Association with thrombin generation, endothelial injury and platelet activation. <i>Thrombosis Research</i> , 2015, 136, 408-414.	0.8	37
164	Exercise stress testing enhances blood coagulation and impairs fibrinolysis in asymptomatic aortic valve stenosis. <i>Journal of Cardiology</i> , 2015, 65, 501-507.	0.8	4
165	Shotgun analysis of plasma fibrin clot-bound proteins in patients with acute myocardial infarction. <i>Thrombosis Research</i> , 2015, 135, 754-759.	0.8	10
166	The use of rivaroxaban in patients with antiphospholipid syndrome: A series of 12 cases. <i>Thrombosis Research</i> , 2015, 135, 1035-1036.	0.8	46
167	Low fasting glucose is associated with enhanced thrombin generation and unfavorable fibrin clot properties in type 2 diabetic patients with high cardiovascular risk. <i>Cardiovascular Diabetology</i> , 2015, 14, 44.	2.7	19
168	Preoperative platelet aggregation predicts perioperative blood loss and rethoracotomy for bleeding in patients receiving dual antiplatelet treatment prior to coronary surgery. <i>Thrombosis Research</i> , 2015, 136, 519-525.	0.8	19
169	Vitamin K antagonists favourably modulate fibrin clot properties in patients with atrial fibrillation as early as after 3 days of treatment: Relation to coagulation factors and thrombin generation. <i>Thrombosis Research</i> , 2015, 136, 832-838.	0.8	20
170	Protein N-linked homocysteine is associated with recurrence of venous thromboembolism. <i>Thrombosis Research</i> , 2015, 136, 911-916.	0.8	4
171	Unfavorably Altered Fibrin Clot Properties in Patients with Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Association with Thrombin Generation and Eosinophilia. <i>PLoS ONE</i> , 2015, 10, e0142167.	1.1	10
172	Determinants of Elevated Levels of Natural Anticoagulants in Healthy Subjects. <i>Advances in Clinical and Experimental Medicine</i> , 2015, 24, 791-800.	0.6	6
173	Arterial and Venous Thromboembolism in Chronic Obstructive Pulmonary Disease: From Pathogenic Mechanisms to Prevention and Treatment. <i>Pneumonologia i Alergologia Polska</i> , 2015, 83, 485-494.	0.6	14
174	Altered fibrin clot structure/function in patients with antiphospholipid syndrome: association with thrombotic manifestation. <i>Thrombosis and Haemostasis</i> , 2014, 112, 287-296.	1.8	27
175	Modulation of Inflammatory and Hemostatic Markers in Obstructive Sleep Apnea Patients Treated with Mandibular Advancement Splints: A Parallel, Controlled Trial. <i>Journal of Clinical Sleep Medicine</i> , 2014, 10, 255-262.	1.4	35
176	The Relationship between Total Serum IgE Levels and Atopic Sensitization in Subjects with or without Atopic Dermatitis. <i>Allergy International</i> , 2014, 63, 485-486.	1.4	3
177	Altered plasma fibrin clot properties and fibrinolysis in patients with multiple myeloma. <i>European Journal of Clinical Investigation</i> , 2014, 44, 557-566.	1.7	21
178	Weight Reduction Is Associated With Increased Plasma Fibrin Clot Lysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2014, 20, 832-837.	0.7	7
179	PROS1 mutations associated with protein S deficiency in Polish patients with residual vein obstruction on rivaroxaban therapy. <i>Thrombosis Research</i> , 2014, 134, 199-201.	0.8	24
180	Polyunsaturated omega-3 fatty acids reduce lipoprotein-associated phospholipase A2 in patients with stable angina. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 434-439.	1.1	25

#	ARTICLE	IF	CITATIONS
181	Abnormalities in blood coagulation, fibrinolysis, and platelet activation in adult patients after the Fontan procedure. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 147, 1284-1290.	0.4	80
182	Coronary thrombus composition: Links with inflammation, platelet and endothelial markers. <i>Atherosclerosis</i> , 2014, 237, 555-561.	0.4	64
183	Prothrombotic alterations in plasma fibrin clot properties in thyroid disorders and their post-treatment modifications. <i>Thrombosis Research</i> , 2014, 134, 510-517.	0.8	13
184	Fibrin clot properties and their modulation in thrombotic disorders. <i>Thrombosis and Haemostasis</i> , 2014, 112, 32-42.	1.8	117
185	Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis. <i>Thrombosis and Haemostasis</i> , 2014, 111, 685-693.	1.8	59
186	Calcification of aortic human valves studied <i>in situ</i> by Raman microimaging: following mineralization from small grains to big deposits. <i>Journal of Raman Spectroscopy</i> , 2013, 44, 1222-1229.	1.2	20
187	Altered plasma fibrin clot properties in patients with digestive tract cancers: Links with the increased thrombin generation. <i>Thrombosis Research</i> , 2013, 131, 262-267.	0.8	23
188	Atherosclerosis and venous thromboembolism – similarities. <i>Kardiologia Polska</i> , 2013, 71, 1223-1228.	0.3	9
189	Factors associated with the presence of circulating active tissue factor and activated factor XI in stable angina patients. <i>Blood Coagulation and Fibrinolysis</i> , 2012, 23, 189-194.	0.5	15
190	Plasma fibrin clot properties in arterial hypertension and their modification by antihypertensive medication. <i>Thrombosis Research</i> , 2012, 130, 99-103.	0.8	29
191	Factor XIII expression within aortic valves and its plasma activity in patients with aortic stenosis: association with severity of disease. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1172-1179.	1.8	18
192	A history of early stent thrombosis is associated with prolonged clot lysis time. <i>Thrombosis and Haemostasis</i> , 2012, 107, 513-520.	1.8	37
193	Does Diabetes Accelerate the Progression of Aortic Stenosis through Enhanced Inflammatory Response within Aortic valves?. <i>Inflammation</i> , 2012, 35, 834-840.	1.7	44
194	Active tissue factor and activated factor XI in patients with acute ischemic cerebrovascular events. <i>European Journal of Clinical Investigation</i> , 2012, 42, 123-129.	1.7	24
195	Altered fibrin clot properties in patients with premature peripheral artery disease. <i>Polish Archives of Internal Medicine</i> , 2012, 122, 608-616.	0.3	11
196	Thrombin generation in chronic obstructive pulmonary disease: Dependence on plasma factor composition. <i>Thrombosis Research</i> , 2011, 128, e24-e28.	0.8	37
197	Circulating activated factor XI and active tissue factor as predictors of worse prognosis in patients following ischemic cerebrovascular events. <i>Thrombosis Research</i> , 2011, 128, e62-e66.	0.8	32
198	Fibrin Clot Structure and Function. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, e88-99.	1.1	422

#	ARTICLE	IF	CITATIONS
199	Acquired dysfibrinogenemia in atherosclerotic vascular disease. , 2011, 121, 310-9.		6
200	Shorter preoperative fibrin clot lysis time predisposes to higher chest tube drainage in patients undergoing elective coronary artery bypass grafting surgery. <i>Blood Coagulation and Fibrinolysis</i> , 2010, 21, 380-381.	0.5	11
201	Altered fibrin clot properties in patients with chronic heart failure and sinus rhythm: a novel prothrombotic mechanism. <i>Heart</i> , 2010, 96, 1114-1118.	1.2	28
202	Architecture of a pulmonary thrombus removed during embolectomy in a patient with acute pulmonary embolism. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2010, 140, e40-e41.	0.4	9
203	Fibrin clot properties in acute ischemic stroke: relation to neurological deficit. <i>Thrombosis Research</i> , 2010, 125, 357-361.	0.8	83
204	Effect of cigarette smoking on plasma fibrin clot permeability and susceptibility to lysis. <i>Thrombosis and Haemostasis</i> , 2009, 102, 1289-1291.	1.8	40
205	Altered Fibrin Clot Structure/Function in Patients With Cryptogenic Ischemic Stroke. <i>Stroke</i> , 2009, 40, 1499-1501.	1.0	113
206	Systemic blood coagulation activation in acute coronary syndromes. <i>Blood</i> , 2009, 113, 2070-2078.	0.6	61
207	Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. <i>Blood</i> , 2009, 114, 4272-4278.	0.6	226
208	Architecture of intra-atrial thrombi in patients with severe mitral stenosis. <i>Journal of Heart Valve Disease</i> , 2009, 18, 496-8.	0.5	3
209	Factor XIa and tissue factor activity in patients with coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2008, 99, 142-149.	1.8	76
210	Blood coagulation at the site of microvascular injury: effects of low-dose aspirin. <i>Blood</i> , 2001, 98, 2423-2431.	0.6	84
211	Simvastatin Depresses Blood Clotting by Inhibiting Activation of Prothrombin, Factor V, and Factor XIII and by Enhancing Factor Va Inactivation. <i>Circulation</i> , 2001, 103, 2248-2253.	1.6	255
212	Relationship between bleeding time, aspirin and the PIA1/A2 polymorphism of platelet glycoprotein IIIa. <i>British Journal of Haematology</i> , 2000, 110, 965-967.	1.2	120
213	Pathogenesis of Vascular Disease in Hyperhomocysteinaemia. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1998, 5, 239-247.	3.1	26
214	Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies. <i>The Cochrane Library</i> , 0, , .	1.5	3